A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 4)
Condition(s):Mild Cognitive Impairment (MCI); Alzheimer DiseaseLast Updated:November 2, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Mild Cognitive Impairment (MCI); Alzheimer DiseaseLast Updated:November 2, 2023Completed
Condition(s):Alzheimer DiseaseLast Updated:January 31, 2024Enrolling by invitation
Condition(s):Alzheimer Disease; Dementia Frontal; Mild Cognitive ImpairmentLast Updated:August 23, 2018Unknown status
Condition(s):Vascular Cognitive Impairment; Mild Cognitive ImpairmentLast Updated:January 30, 2024Recruiting
Condition(s):Alzheimer Disease; Mild Cognitive ImpairmentLast Updated:August 1, 2023Recruiting
Condition(s):Healthy; Alzheimer DiseaseLast Updated:March 18, 2014Completed
Condition(s):Mild Cognitive ImpairmentLast Updated:January 26, 2012Terminated
Condition(s):Endarterectomy; Postoperative Cognitive DysfunctionLast Updated:September 22, 2016Completed
Condition(s):Cognitive Decline; Mild Cognitive Impairment; Alzheimer DiseaseLast Updated:October 7, 2022Recruiting
Condition(s):Alzheimer Disease; Frontotemporal Dementia; Dementia, Vascular; Mild Cognitive ImpairmentLast Updated:May 4, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.